Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. John's Doctor H. OncologyResearchSupport providence. Stevenson foundationhealth. Carvell bmhcc. Boucher providence.
Couey ucsf. Research flhosp. Research rushcopley. Norris LMH. Zimmerman vidanthealth. Dodd providence. To evaluate whether therapy with nivolumab following combined modality therapy CMT improves disease-free survival DFS compared with observation in patients with high risk anal carcinoma.
To compare nivolumab following combined modality therapy CMT with observation in patients with high risk anal carcinoma with regard to: Ia. Objective response rate complete [CR] and partial [PR] , stable disease and progression.
Severe toxicity interval. Colostomy-free survival. Overall survival. ARM B: Patients undergo observation while on study Patients undergo sigmoidoscopy, colonoscopy or anoscopy, proctoscopy or digital rectal exam, x-ray, computed tomography CT scan, magnetic resonance imaging MRI , biopsy and blood sample collection throughout the study. Interactive content above is from the official study record on the National Cancer Institute website, cancer. Anus Cancer EA Newfoundland St. AR Ft. Review Active Trials.
